Personally tailored intervention generates patient interest, QoL improvements.
Cheryl Guttman Krader
Benefit evident regardless of metastasis site, phase III analysis shows.
~40% of sipuleucel-T recipients in lowest PSA quartile alive after 5 years.
Although active surveillance for prostate cancer is on the rise in younger, privately insured men, many patients do not undergo a repeat biopsy.
The combination appears to be a more powerful predictor than mpMRI/PSA density.
Retrospective analyses of data collected in a real-world study provide assurance about using nivolumab (Opdivo) to treat elderly patients with metastatic renal cell carcinoma who have failed previous therapy.
“We believe that our study underscores the importance of improving dissemination of the guidelines and their implementation and uptake in practice,” says researcher Nikhil Waingankar, MD, MSHP.
Apalutamide (Erleada) treatment in men with nonmetastatic castrate-resistant prostate cancer significantly improves metastasis-free survival and does so without adversely affecting health-related quality of life.
“A multivariable analysis confirmed that AR-V7 status independently predicted PSA response,” says researcher Matthias Heck, MD.
Findings from a retrospective analysis of data collected at the National Institutes of Health provide insight on how multiparametric MRI/transrectal ultrasound-fusion biopsy (“fusion biopsy”) may be affecting management patterns and outcomes for men with prostate cancer.